Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Chia

Showing results (221-230 of 256) with videos related to

Pageof 26
Sort By:
Breast (Edinburgh, Scotland)|June 16, 2026
Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimizationG Curigliano, L Marotti, C Barrios, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimizationG Curigliano, L Marotti, C Barrios, et al.
Annals of Surgical Oncology|September 6, 2023
Implementation of a Multi-Disciplinary Team and Quality of Goals of Care Discussions in Palliative Surgical Oncology PatientsJoel J Y Soon, Darryl W K Juan, Whee S Ong, et al.
Nature|November 8, 2016
S-2-hydroxyglutarate regulates CD8<sup>+</sup> T-lymphocyte fatePetros A Tyrakis, Asis Palazon, David Macias, et al.
JCO Oncology Practice|January 13, 2021
Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response TaskforceJin Wei Kwek, Jack J Chan, Ravindran Kanesvaran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Mbio|May 7, 2015
Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteriaWilfried Moreira, Grace J Y Ngan, Jian Liang Low, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neckA R Abdul Razak, D Soulières, S A Laurie, et al.
Pageof 26

Showing results (221-230 of 256) with videos related to

Sort By:
Pageof 26
Breast (Edinburgh, Scotland)|June 16, 2026
Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimizationG Curigliano, L Marotti, C Barrios, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimizationG Curigliano, L Marotti, C Barrios, et al.
Annals of Surgical Oncology|September 6, 2023
Implementation of a Multi-Disciplinary Team and Quality of Goals of Care Discussions in Palliative Surgical Oncology PatientsJoel J Y Soon, Darryl W K Juan, Whee S Ong, et al.
Nature|November 8, 2016
S-2-hydroxyglutarate regulates CD8<sup>+</sup> T-lymphocyte fatePetros A Tyrakis, Asis Palazon, David Macias, et al.
JCO Oncology Practice|January 13, 2021
Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response TaskforceJin Wei Kwek, Jack J Chan, Ravindran Kanesvaran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Mbio|May 7, 2015
Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteriaWilfried Moreira, Grace J Y Ngan, Jian Liang Low, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neckA R Abdul Razak, D Soulières, S A Laurie, et al.
Pageof 26